Stockreport

Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases [Yahoo! Finance]

Xencor, Inc.  (XNCR) 
Last xencor, inc. earnings: 2/24 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.xencor.com/investor-relations
PDF XmAb942 is a high-potency, extended half-life, investigational anti-TL1A antibody to be developed for patients with inflammatory bowel diseases, such as ulcerative coli [Read more]